|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
WO2021207291A1
(en)
*
|
2020-04-06 |
2021-10-14 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
EP4259144A4
(en)
*
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
US11993599B2
(en)
|
2021-08-09 |
2024-05-28 |
Genentech, Inc. |
Therapeutic compounds
|
|
WO2023129506A1
(en)
*
|
2021-12-28 |
2023-07-06 |
Board Of Regents, The University Of Texas System |
Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics
|
|
EP4476225A4
(en)
*
|
2022-02-09 |
2026-01-14 |
Aurigene Oncology Ltd |
PYRIDAZINE 3-SUBSTITUTED COMPOUNDS USED AS SMARCA2 AND/OR SMARCA4 DEGRADING AGENTS
|
|
KR20250023362A
(ko)
*
|
2022-06-15 |
2025-02-18 |
씨4 테라퓨틱스, 인코포레이티드 |
Smarca2의 표적화된 분해를 위한 화합물
|
|
CN119384414A
(zh)
*
|
2022-06-30 |
2025-01-28 |
甘李药业股份有限公司 |
一种用作smarca2/4抑制剂的化合物及其应用
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024064328A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 degraders and uses thereof
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
WO2024137742A1
(en)
|
2022-12-20 |
2024-06-27 |
Blueprint Medicines Corporation |
Compounds and compositions as fgfr3 degraders and uses thereof
|
|
WO2025096976A1
(en)
*
|
2023-11-01 |
2025-05-08 |
Cornell University |
Arid1a is a prognostic marker for aggressive lymphoma transformation and presents a vulnerability to pharmacological inhibition of smarca4/2
|
|
WO2025129116A1
(en)
*
|
2023-12-14 |
2025-06-19 |
C4 Therapeutics, Inc. |
Compounds for the targeted degradation of smarca2
|